Raymond James & Associates Cidara Therapeutics, Inc. Transaction History

Raymond James & Associates

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$0.45 - $13.0 $5,252 - $151,736	11,672 New	11,672 $7,000
Q3 2020 Nov 04, 2020	SELL	$2.85 - $4.1 $39,438 - $56,735	-13,838 Closed	0 $0
Q2 2020 Jul 28, 2020	BUY	$2.39 - $4.0 $33,072 - $55,352	13,838 New	13,838 $51,000
Q1 2020 Apr 21, 2020	SELL	$1.74 - $4.26 $20,445 - $50,055	-11,750 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$1.77 - $3.84 $2,212 - $4,800	-1,250 Reduced 9.62%	11,750 $45,000
Q3 2019 Nov 07, 2019	SELL	$1.25 - $2.35 $302,500 - $568,700	-242,000 Reduced 94.9%	13,000 $26,000
Q2 2019 Aug 06, 2019	SELL	$1.49 - $2.94 $66,553 - $131,320	-44,667 Reduced 14.91%	255,000 $428,000
Q1 2019 May 06, 2019	SELL	$2.35 - $3.27 $74,457 - $103,606	-31,684 Reduced 9.56%	299,667 $794,000
Q4 2018 Feb 11, 2019	BUY	$2.1 - $4.5 $192,261 - $411,988	91,553 Added 38.18%	331,351 $779,000
Q3 2018 Nov 14, 2018	BUY	$3.7 - $5.25 $162,504 - $230,580	43,920 Added 22.42%	239,798 $1.06 Million
Q2 2018 Aug 14, 2018	BUY	$3.75 - $6.05 $374,726 - $604,558	99,927 Added 104.14%	195,878 $1.02 Million
Q1 2018 May 14, 2018	BUY	$4.0 - $8.15 $283,872 - $578,389	70,968 Added 284.07%	95,951 $384,000
Q4 2017 Feb 14, 2018	SELL	$6.35 - $8.75 $39,516 - $54,451	-6,223 Reduced 19.94%	24,983 $170,000
Q3 2017 Nov 13, 2017	BUY	$5.75 - $8.1 $36,098 - $50,851	6,278 Added 25.18%	31,206 $253,000
Q2 2017 Aug 14, 2017	BUY	N/A	24,928	24,928 $187,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.24B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.